Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies.
CONCLUSION: The present study is the first analysis of Czech data from the Registry of Monoclonal Gammopathies, and it provides important insights into the real-world management of MM for physicians and healthcare providers. PMID: 29793653 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 29, 2018 Category: Cancer & Oncology Authors: Hájek R, Jarkovsky J, Maisnar V, Pour L, Špička I, Minařík J, Gregora E, Kessler P, Sýkora M, Fraňková H, Campioni M, DeCosta L, Treur M, Gonzalez-McQuire S, Bouwmeester W Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Cutaneous sarcoidosis: a new subset in the spectrum of paraneoplastic dermatoses.
CONCLUSION: Our results suggest that sarcoidosis is a new subset in the spectrum of paraneoplastic syndrome. We propose that lymphoproliferative disorders should be considered in patients with cutaneous sarcoidosis who have a poor response to conventional therapy or whose skin biopsy shows a significant number of mitoses. PMID: 29779211 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 20, 2018 Category: Cancer & Oncology Authors: El-Khalawany M, Mosbeh A, Aboeldahab S, Ali S Tags: Clin Exp Dermatol Source Type: research

Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 527 Patients From the Polish Adult Leukemia Group Registry.
PMID: 29778693 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 9, 2018 Category: Cancer & Oncology Authors: Gora-Tybor J, Sacha T, Wącław J, Niesiobędzka-Krężel J, Grzybowska-Izydorczyk O, Mędraś E, Dereń-Wagemann I, Patkowska E, Seferyńska I, Lewandowski K, Wache A, Blajer-Olszewska B, Wątek M, Kotwica-Mojzych K, Wasilewska E, Warzocha K, Jamroziak K Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational  Study.
CONCLUSION: In real life, ponatinib is a "niche-drug" reserved for a unique population of exceptionally young patients with CML with or without the T315I mutation. In this highly selected group, very different from the PACE cohort, ponatinib achieved high overall response rates. PMID: 29773429 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 7, 2018 Category: Cancer & Oncology Authors: Shacham-Abulafia A, Raanani P, Lavie D, Volchek Y, Ram R, Helman I, Shargian L, Gourevitch A, Chubar E, Ratzon R, Rozovski U Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Surrogate Endpoints and Risk Adaptive Strategies in Previously Untreated Follicular Lymphoma.
Abstract Follicular lymphoma is the second most common subtype of non-Hodgkin lymphoma with an estimated 3.18 cases per 100,000 people. Despite the prolongation of survival with chemoimmunotherapy, variability in response to initial treatment and outcome still exists. Whereas prolonging overall survival is important, it is generally an unreasonable primary endpoint in the front-line setting. The long follow-up needed and the influence of subsequent therapies creates a potential bias. Thus, clinical trials require approximately 5 to 8 years from activation to completion and analysis of outcomes. This duration resul...
Source: Clinical Lymphoma and Myeloma - May 5, 2018 Category: Cancer & Oncology Authors: Narkhede MS, Cheson BD Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Successful Use of Bortezomib-Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma.
las F PMID: 29753690 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 4, 2018 Category: Cancer & Oncology Authors: Marrero WD, Cruz-Chacón A, Castillo C, Cabanillas F Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study.
We present a retrospective analysis to compare the hematologic and organ response in patients who received bortezomib-based therapy before autologous stem cell transplantation (ASCT) versus those who received non-bortezomib-based therapy before ASCT and those who underwent ASCT at diagnosis. PATIENTS AND METHODS: Of a total of 63 patients who underwent ASCT for light chain amyloidosis, 34 received bortezomib-based therapy before ASCT (Bor-ASCT) and 29 did not receive bortezomib therapy (non-Bor-ASCT). A greater number of patients had involvement of ≥ 3 organs and cardiac involvement in the Bor-ASCT group, sugg...
Source: Clinical Lymphoma and Myeloma - May 4, 2018 Category: Cancer & Oncology Authors: Jain T, Kosiorek HE, Kung ST, Shah VS, Dueck AC, Gonzalez-Calle V, Luft S, Reeder CB, Adams R, Noel P, Larsen JT, Mikhael J, Bergsagel L, Stewart AK, Fonseca R Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Natural Killer/T-cell Neoplasms: Analysis of Incidence, Patient Characteristics, and Survival Outcomes in the United States.
Abstract BACKGROUND: Limited data are available regarding the incidence, survival patterns, and long-term outcomes of natural killer (NK)/T-cell neoplasms in the United States. PATIENTS AND METHODS: We performed a retrospective study of patients with NK/T-cell neoplasms diagnosed from 2001 to 2014 using the Surveillance, Epidemiology, and End Results program database. The Kaplan-Meier method was used to estimate the overall survival difference among the subgroups. Multivariate analyses were used to determine the factors affecting survival. RESULTS: For the 797 patients with NK/T-cell lymphoma, nasal type...
Source: Clinical Lymphoma and Myeloma - May 4, 2018 Category: Cancer & Oncology Authors: Kommalapati A, Tella SH, Ganti AK, Armitage JO Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Treatment of Vulvar Mycosis Fungoides Tumors With Localized Radiotherapy.
PMID: 29752211 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 4, 2018 Category: Cancer & Oncology Authors: Geller S, Pitter K, Moskowitz A, Horwitz SM, Yahalom J, Myskowski PL Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Cytogenetic Profile of Moroccan Pediatric Acute Lymphoblastic Leukemia: Analysis of 155 Cases With a Review of the Literature.
CONCLUSION: The frequency of most chromosomal rearrangements successfully identified in our study and their lineage correlated with those reported in the published data. PMID: 29748040 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 25, 2018 Category: Cancer & Oncology Authors: Chebihi ZT, Belkhayat A, Chadli E, Hilal L, Skhoun H, Hessissen L, El Khorassani M, El Kababri M, Kili A, Khattab M, Bakri Y, Dakka N Tags: Clin Lymphoma Myeloma Leuk Source Type: research

PD-1 Blocks Lytic Granule Polarization with Concomitant Impairment of Integrin 'Outside-in' Signaling in Natural Killer Cell Immunological Synapse.
CONCLUSION: Our results suggest that NK cell cytotoxicity is inhibited by PD-1 engagement, which blocks lytic granule polarization to NK cell immunological synapse with concomitant impairment of integrin 'outside-in' signaling. This study provides novel mechanistic insights into how PD-1 inhibition disrupts NK cell function. PMID: 29679656 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 18, 2018 Category: Cancer & Oncology Authors: Huang Y, Chen Z, Jang JH, Baig MS, Bertolet G, Schroeder C, Huang S, Hu Q, Zhao Y, Lewis DE, Qin L, Zhu MX, Liu D Tags: J Allergy Clin Immunol Source Type: research

La/SSB chimeric autoantibody receptor modified NK92MI cells for targeted therapy of autoimmune disease.
Abstract It has been long sought to specifically eliminate B-cell clones that generate autoreactive antibodies, while sparing the immune system when combating autoimmune disease. Although it was impossible to achieve this goal before, newly developed techniques have made it feasible today. Autoantibodies against La/SSB were involved in several autoimmune diseases. Here, we aimed to introduce La/SSB epitope-based chimeric autoantibody receptors (CAAR) into NK92MI cells enabled it to destroy the corresponding La/SSB-specific B cell receptor (BCR) -bearing lymphoma cells (LaA-BCR-Romas, LaA-BCR-Maver-1, and LaA-BCR-J...
Source: Clinical Lymphoma and Myeloma - April 16, 2018 Category: Cancer & Oncology Authors: Meng H, Sun X, Song Y, Zou J, An G, Jin Z, Yang L Tags: Clin Immunol Source Type: research

"Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions"-Treatment of ALL.
"Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions"-Treatment of ALL. Clin Lymphoma Myeloma Leuk. 2018 Apr 03;: Authors: Chiaretti S, Jabbour E, Hoelzer D Abstract The outcome of adult acute lymphoblastic leukemia (ALL) has substantially improved by adopting pediatric-inspired regimens, and approximately half of the patients are nowadays cured. The evaluation of minimal residual disease currently represents the most important prognostic indicator, which drives treatment algorithms, which include allogeneic stem cell transplantation (allo-SCT) allocation. Inde...
Source: Clinical Lymphoma and Myeloma - April 3, 2018 Category: Cancer & Oncology Authors: Chiaretti S, Jabbour E, Hoelzer D Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Optia ® continuous mononuclear collection (CMNC) system is a safe and efficient system for hematopoietic progenitor cells-apheresis (HPC-a) collection and yields a lower product hematocrit (HCT%) than the COBE® spectra system: A retrospective study.
Optia® continuous mononuclear collection (CMNC) system is a safe and efficient system for hematopoietic progenitor cells-apheresis (HPC-a) collection and yields a lower product hematocrit (HCT%) than the COBE® spectra system: A retrospective study. J Clin Apher. 2018 Mar 30;: Authors: Pandey S, Cottler-Fox M Abstract PURPOSE: We evaluated the Optia® continuous mononuclear collection (CMNC) system for hematopoietic progenitor cell-apheresis (HPC-A) collection (Terumo BCT, Lakewood, CO) compared to the COBE® Spectra (Terumo BCT, Lakewood, CO), including both large volume leukapheresis (L...
Source: Clinical Lymphoma and Myeloma - March 30, 2018 Category: Cancer & Oncology Authors: Pandey S, Cottler-Fox M Tags: J Clin Apher Source Type: research

Impact of apheresis automation on procedure quality and predictability of CD34+ cell yield.
Abstract Success of peripheral blood stem cell (PBSC) collections depends on patient biological parameters and stable apheresis device performance. We investigated product quality and factors influencing main apheresis procedure outcomes including CD34+ collection efficiency (CE), product volume or platelet CE. We also assessed different CD34+ cell yield prediction algorithms. Autologous PBSC collections by Spectra Optia from myeloma and lymphoma patients were analyzed. Complete blood count (CBC) from patient preprocedure and from collected products were assessed. (1) Product yield was calculated, (2) Product CBC ...
Source: Clinical Lymphoma and Myeloma - March 23, 2018 Category: Cancer & Oncology Authors: Besson N, Topholm Bruun M, Stauffer Larsen T, Nielsen C Tags: J Clin Apher Source Type: research

Fluoroquinolone prophylaxis during neutropenia: what can we expect nowadays?
Abstract Yeshurun et al. reported the results of retrospective study with historical control in patients with multiple myeloma and lymphoma undergoing autologous transplant. The rates of bacteraemia and fever were lower during the period of ciprofloxacin prophylaxis with no effect on mortality. In the era of multidrug resistance (MDR), the efficacy of fluoroquinolone prophylaxis might be lower in settings with high level of resistance. Additionally, the benefit of fluoroquinolone prophylaxis on mortality should not be expected since the morality is mainly associated with infections due to MDR currently associated ...
Source: Clinical Lymphoma and Myeloma - March 13, 2018 Category: Cancer & Oncology Authors: Mikulska M, Cordonnier C Tags: Clin Microbiol Infect Source Type: research

Monoclonal gammopathy in rheumatic diseases.
Abstract To analyze the clinical spectrum, laboratory characteristics, and outcomes of monoclonal gammopathy (MG) in patients with rheumatic diseases. Screening for the presence of MG was performed in 872 inpatients with rheumatic diseases from January 2010 to July 2017. A total of 41 patients were enrolled. Their clinical and biological features in addition to outcomes were described. For each patient with primary Sjögren syndrome (pSS), 2 age- and sex-matched pSS patients without MG were selected as controls. Risk factors for the presence of MG and malignant hematological neoplasias were assessed. MG was ob...
Source: Clinical Lymphoma and Myeloma - March 13, 2018 Category: Cancer & Oncology Authors: Yang Y, Chen L, Jia Y, Liu Y, Wen L, Liang Y, An Y, Chen S, Su Y, Li Z Tags: Clin Rheumatol Source Type: research

Interim PET Response-adapted Strategy in Untreated Advanced Stage Hodgkin Lymphoma: Results of GOELAMS LH 2007 Phase 2 Multicentric Trial.
CONCLUSION: A PET-guided strategy with early salvage therapy and high-dose therapy/autologous stem cell transplantation for patients with interim PET-2-positive findings is safe and feasible and provide similar outcome as patients with a negative PET-2. PMID: 29502594 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 1, 2018 Category: Cancer & Oncology Authors: Carras S, Dubois B, Senecal D, Jais JP, Peoc'h M, Quittet P, Foussard C, Bouabdallah K, Gastinne T, Jourdan E, Sanhes L, Ertault M, Lamy T, Molina L Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium-Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-Cell Lymphoma.
Conclusions:Administering ASCT with rituximab during stem cell collection and immediately after transplantation induces long-term disease remission and abolishes the negative prognostic impact of cell-of-origin in patients with relapsed DLBCL. The addition of 90YIT does not confer a further survival benefit. PMID: 29476021 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 23, 2018 Category: Cancer & Oncology Authors: Chahoud J, Sui D, Erwin WD, Gulbis AM, Korbling M, Zhang M, Ahmed S, Alatrash G, Anderlini P, Ciurea SO, Oran B, Fayad L, Bassett RL, Jabbour E, Medeiros LJ, Macapinlac HA, Young KH, Khouri IF Tags: Clin Cancer Res Source Type: research

Abnormal Heavy/Light Chain Ratio and Matched Pair Suppression Increase Residual Disease Detection Sensitivity in Patients With Multiple Myeloma With Deep Responses.
Abstract BACKGROUND: Heavy/light chain (HLC) assay can quantify involved as well as uninvolved immunoglobulin pairs and is used to detect monoclonal proteins. PATIENTS AND METHODS: We compared the sensitivity between HLC assay and serum protein electrophoresis, serum immunofixation electrophoresis (IFE), and free light chain (FLC) assay in patients with symptomatic multiple myeloma (n = 111) whose responses were stable disease or better. RESULTS: Among patients with negative IFE and normal FLC ratios, 84.4% (38 of 45) and 80% (36 of 45) exhibited normal HLC ratios and no pair suppression, respective...
Source: Clinical Lymphoma and Myeloma - February 19, 2018 Category: Cancer & Oncology Authors: Miyazaki K, Suzuki K Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'.
PMID: 29434334 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 13, 2018 Category: Cancer & Oncology Authors: Neelapu SS, Tummala S, Kebriaei P, Wierda W, Locke FL, Lin Y, Jain N, Daver N, Gulbis AM, Adkins S, Rezvani K, Hwu P, Shpall EJ Tags: Nat Rev Clin Oncol Source Type: research

Challenges and Opportunities for High-grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma).
Abstract The most common subtype of non-Hodgkin lymphoma, diffuse large B-cell lymphoma, is cured in approximately two thirds of patients after initial therapy. The remaining one-third of patients who suffer relapse or become refractory have very poor survival outcomes despite salvage chemotherapy with or without stem cell transplantation. A considerable proportion of relapsed or refractory large B cells belong to the WHO subtype known as high-grade B-cell lymphoma with rearrangement of MYC and BCL2 and/or BCL6, also known as double-hit lymphoma (DHL). Most DHL patients present with Ann Arbor's stage III/IV, a com...
Source: Clinical Lymphoma and Myeloma - February 6, 2018 Category: Cancer & Oncology Authors: Zeng D, Desai A, Yan F, Gong T, Ye H, Ahmed M, Nomie K, Romaguera J, Champlin R, Li S, Wang M Tags: Am J Clin Oncol Source Type: research

Outcome of Chronic Myeloid Leukemia-Chronic Phase Patients Treated With Imatinib: A Local Experience.
CONCLUSION: After a median follow-up of 8 years, imatinib was found to induce long survival with manageable side effect in adult Saudi patients with CML-CP. PMID: 29397347 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 31, 2018 Category: Cancer & Oncology Authors: Al-Amri AM Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Crystal-Storing Histiocytosis in Bone Marrow: A Clinicopathologic Study of Eight Cases and Review of the Literature.
Conclusions: BM-CSH is a rare phenomenon and exhibits a heterogeneous crystalline and histiocytic appearance warranting accurate recognition to avoid misinterpretation of a granulomatous condition or storage disorder. In addition, prompt assessment for an underlying B-cell lymphoma or clonal plasmacytic neoplasm is indicated. PMID: 29385417 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 29, 2018 Category: Cancer & Oncology Authors: Fang H, Chiu A, Reichard KK Tags: Am J Clin Pathol Source Type: research

The Impact of Reported Beta-Lactam Allergy in Hospitalized Patients with Hematologic Malignancies Requiring Antibiotics.
Abstract Background: Patients hospitalized with hematologic malignancy are particularly vulnerable to infection. The impact of reported beta-lactam (BL) allergy in this population remains unknown. Objective: To define the impact of reported BL-only allergy (BLOA) label on clinical outcomes compared to those with no BL allergy (NBLA) in hematologic malignancy inpatients requiring systemic antibiotics. Methods: Retrospective cohort study of adult inpatients with hematologic malignancy admitted at two tertiary care hospitals 2010-2015. The primary outcome was hospital length of stay (LOS) after first antibi...
Source: Clinical Lymphoma and Myeloma - January 16, 2018 Category: Cancer & Oncology Authors: Huang KG, Cluzet V, Hamilton K, Fadugba O Tags: Clin Infect Dis Source Type: research

HIV-related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab.
PMID: 29342442 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 3, 2018 Category: Cancer & Oncology Authors: Chang E, Rivero G, Patel NR, Chiao EY, Lai S, Bajaj K, Mbue JE, Yellapragada SV Tags: Clin Lymphoma Myeloma Leuk Source Type: research

SOHO State-of-the-Art Update and Next Questions: MPN.
Abstract The discovery of the activating Janus kinase (JAK)2V617F mutation in 2005 in most patients with the classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) spurred intense interest in research into these disorders, culminating in the identification of activating mutations in MPL in 2006 and indels in the gene encoding calreticulin (CALR) in 2013, thus providing additional mechanistic explanations for the universal activation of JAK-signal transducer and activator of transcription (JAK-STAT) observed in these conditions, and the success of the JAK1/2 inhibitor ruxolitinib, which first r...
Source: Clinical Lymphoma and Myeloma - December 28, 2017 Category: Cancer & Oncology Authors: Bose P, Gotlib J, Harrison CN, Verstovsek S Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes.
CONCLUSION: Our results suggest that achievement of a CR is imperative in patients with advanced ENKL, and is desirable for any patient for whom auto-SCT is utilized. SMILE-based chemotherapy appeared effective in attaining a CR, and was also an effective salvage regimen. For patients attaining a first CR, auto-SCT should be strongly considered, but should definitely be utilized in patients attaining CR2. For patients with refractory disease, allo-SCT can be considered in a selected group of patients. PMID: 29277360 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 28, 2017 Category: Cancer & Oncology Authors: Brammer JE, Chihara D, Poon LM, Caimi P, de Lima M, Ledesma C, Rondon G, Ciurea SO, Nieto Y, Fanale M, Dabaja B, Maziarz RT, Champlin RE, Hosing C, Oki Y Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
Abstract Immunotherapy using T cells genetically engineered to express a chimeric antigen receptor (CAR) is rapidly emerging as a promising new treatment for haematological and non-haematological malignancies. CAR-T-cell therapy can induce rapid and durable clinical responses, but is associated with unique acute toxicities, which can be severe or even fatal. Cytokine-release syndrome (CRS), the most commonly observed toxicity, can range in severity from low-grade constitutional symptoms to a high-grade syndrome associated with life-threatening multiorgan dysfunction; rarely, severe CRS can evolve into fulminant ha...
Source: Clinical Lymphoma and Myeloma - December 22, 2017 Category: Cancer & Oncology Authors: Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ Tags: Nat Rev Clin Oncol Source Type: research

Smoldering mantle cell lymphoma.
Abstract BACKGROUND: Mantle cell lymphoma (MCL) is an aggressive disease, with poor prognosis and a limited survival. However, some patients with indolent MCL can survive beyond 7~10 years. These patients remain largely asymptomatic and can be in observation for a long time without any treatment. The process of "wait and watch" leaves these patients with the potential risk of evolution to classic, aggressive MCL. On the other hand, early treatment for these patients may not impact overall survival but rather affects the quality of life. Therefore, it is essential to clearly identify this type of ind...
Source: Clinical Lymphoma and Myeloma - December 15, 2017 Category: Cancer & Oncology Authors: Ye H, Desai A, Zeng D, Nomie K, Romaguera J, Ahmed M, Wang ML Tags: J Exp Clin Cancer Res Source Type: research

How to Approach a Hodgkin Lymphoma Patient With Relapse After Autologous SCT: Allogeneic SCT.
Abstract Hodgkin lymphoma (HL) is a highly curable B-cell lymphoma, and ∼90% of patients who present with early-stage (stage I-II) disease and 70% of patients who present with late-stage disease will be cured with standard frontline treatment. For patients with relapsed or refractory (r/r) disease after initial therapy, the standard of care is salvage chemotherapy, followed by autologous transplantation (autoSCT). Although this approach will cure a significant proportion of patients, upto 50% of patients will experience disease progression after autoSCT, and this population has historically had a very poo...
Source: Clinical Lymphoma and Myeloma - December 9, 2017 Category: Cancer & Oncology Authors: Mei M, Chen R Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma.
CONCLUSION: Allogeneic HSCT is a promising treatment modality for CD8+ PCAETL. Because of the aggressive nature of this disease and lack of sustained remission with currently available therapies, HSCT should be considered early in the course of treatment. Two novel agents, brentuximab and pralatrexate, showed significant activity against CD8+ PCAETL, and may be incorporated earlier in the treatment course. PMID: 29223388 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 6, 2017 Category: Cancer & Oncology Authors: Cyrenne BM, Gibson JF, Subtil A, Girardi M, Isufi I, Seropian S, Foss F Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function.
Abstract Pomalidomide is an immunomodulatory drug for treatment of relapsed or refractory multiple myeloma (rrMM) in patients who often have comorbid renal conditions. To assess the impact of renal impairment on pomalidomide exposure, a population pharmacokinetics (PPK) model of pomalidomide in rrMM patients with various degrees of impaired renal function was developed. Intensive and sparse pomalidomide concentration data collected from two clinical studies in rrMM patients with normal renal function, moderately impaired renal function, severely impaired renal function not requiring dialysis, and with severely imp...
Source: Clinical Lymphoma and Myeloma - December 2, 2017 Category: Cancer & Oncology Authors: Li Y, Wang X, O'Mara E, Dimopoulos MA, Sonneveld P, Weisel KC, Matous J, Siegel DS, Shah JJ, Kueenburg E, Sternas L, Cavanaugh C, Zaki M, Palmisano M, Zhou S Tags: Clin Pharmacol Source Type: research

KLHL6 Is Preferentially Expressed in Germinal Center-Derived B-Cell Lymphomas.
Conclusions: In addition to other germinal center markers, including BCL6, CD10, HGAL, and LMO2, KLHL6 immunohistochemistry may prove a useful adjunct in the diagnosis and future classification of B-cell lymphomas. PMID: 29140403 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 11, 2017 Category: Cancer & Oncology Authors: Kunder CA, Roncador G, Advani RH, Gualco G, Bacchi CE, Sabile JM, Lossos IS, Nie K, Tibshirani RJ, Green MR, Alizadeh AA, Natkunam Y Tags: Am J Clin Pathol Source Type: research

Cognitive dysfunction among newly diagnosed older patients with hematological malignancy: frequency, clinical indicators and predictors.
Conclusions: The prevalence rate of cognitive dysfunction was non-negligible among older patients with hematologic malignancy before and immediately after initial chemotherapy. Attention to the clinical indicators and predictors found in this study may provide facilitate the identification of cognitive dysfunction in patients with cancer. PMID: 29136185 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 10, 2017 Category: Cancer & Oncology Authors: Aiki S, Okuyama T, Sugano K, Kubota Y, Imai F, Nishioka M, Ito Y, Iida S, Komatsu H, Ishida T, Kusumoto S, Akechi T Tags: Jpn J Clin Oncol Source Type: research

Advances in Diagnosis and Management of Diffuse Large B-cell Lymphoma.
Abstract The management of diffuse large B-cell lymphoma (DLBCL) has been gradually evolving since the discovery of its 2 major forms, the germinal center B-like (GCB) and activated B-cell (ABC) types. Although the reference standard for the identification of these cell types is considered gene expression profiling (GEP), currently the only method commercially available is immunohistochemistry (IHC). The application of various IHC-based algorithms and their correlation with GEP and clinical outcome are discussed. Because of the adverse prognostic implications of the non-GCB type and its potential effects on treatm...
Source: Clinical Lymphoma and Myeloma - November 7, 2017 Category: Cancer & Oncology Authors: Cabanillas F, Shah B Tags: Clin Lymphoma Myeloma Leuk Source Type: research

State of the Art Update and Next Questions: Acute Myeloid Leukemia.
Abstract As our general understanding regarding the complex nature of acute myeloid leukemia (AML) is expanding, so is our ability to translate this biological data into clinically relevant information. The use of whole genome and whole exome sequencing has begun to shed light on the importance of a variety of somatic mutations that are frequently identified in AML. In turn, this has allowed the field to incorporate mutational data into prognostic classifications which can guide treatment decisions. Furthermore, minimal residual disease (MRD) monitoring in AML is more commonplace as the prognostic relevance of MRD...
Source: Clinical Lymphoma and Myeloma - November 1, 2017 Category: Cancer & Oncology Authors: Sweet K, Lancet J Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Are We Choosing Wisely in Lymphoma? Excessive Use of Surveillance CT Imaging in Patients With Diffuse Large B-cell Lymphoma (DLBCL) in Long-term Remission.
Abstract INTRODUCTION: The use of surveillance computed tomography (CT) imaging in patients with diffuse large B-cell lymphoma in remission is neither effective nor cost-effective. The American Society of Hematology Choosing Wisely (CW) campaign, in particular, emphasizes the lack of benefit beyond 2 years of completion of therapy. We sought to describe the real-world practice of surveillance imaging. PATIENTS AND METHODS: We used population-based health system administrative databases from Ontario, Canada. We studied a cohort of all adult patients ≥ 18 years with diffuse large B-cell lymphoma who rec...
Source: Clinical Lymphoma and Myeloma - October 9, 2017 Category: Cancer & Oncology Authors: Cheung MC, Mittmann N, Earle CC, Rahman F, Liu N, Singh S Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Hereditary Hemochromatosis Manifesting After Treatment of Paroxysmal Nocturnal Hemoglobinuria With Eculizumab.
PMID: 29102415 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 7, 2017 Category: Cancer & Oncology Authors: Elliott E, Waheed S, Syed S, Eswaran S, Gregory S, Shammo J Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma.
Abstract OBJECTIVE: The aim of this study was to understand the influence of disease and patient characteristics on exposure to daratumumab, an immunoglobulin Gκ (IgGκ) monoclonal antibody, and clinical outcomes in relapsed or refractory multiple myeloma (MM). PATIENTS AND METHODS: Baseline myeloma type, albumin levels, renal/hepatic function, age, sex, race, weight, Eastern Cooperative Oncology Group (ECOG) status, refractory status, and number of prior therapies were evaluated using data from two clinical studies-GEN501 (N = 104) and SIRIUS (N = 124). RESULTS: Daratumuma...
Source: Clinical Lymphoma and Myeloma - October 5, 2017 Category: Cancer & Oncology Authors: Yan X, Clemens PL, Puchalski T, Lonial S, Lokhorst H, Voorhees PM, Usmani S, Richardson PG, Plesner T, Liu K, Orlowski RZ, Losic N, Jansson R, Ahmadi T, Lantz K, Ruixo JJP, Zhou H, Xu XS Tags: Clin Pharmacokinet Source Type: research

Bortezomib as a probable cause of the syndrome of inappropriate antidiuretic hormone secretion: A case report and review of the literature.
Abstract Bortezomib is a proteasome inhibitor that has been widely adopted for the treatment of hematological malignancies, including multiple myeloma and lymphoma, and has been considered significantly more tolerable compared with traditional chemotherapeutic drugs. Bortezomib has some potential side effects that involve a number of systems, including the gastrointestinal, hematological, nervous and musculoskeletal systems; however, involvement of the endocrine system is rare. We herein report the case of a patient treated for multiple myeloma who developed the syndrome of inappropriate antidiuretic hormone secre...
Source: Clinical Lymphoma and Myeloma - September 5, 2017 Category: Cancer & Oncology Authors: Lv CL, Li J Tags: Mol Clin Oncol Source Type: research

Hematopoietic Tumors Primarily Presenting in Bone.
Abstract Hematologic neoplasms that primarily present in bone are rare; this article describes the most common examples of hematologic tumors primarily presenting in bone, including plasma cell myeloma, solitary plasmacytoma of bone, primary non-Hodgkin lymphoma of bone, acute lymphoblastic leukemia/lymphoma, and Langerhans cell histiocytosis. The macroscopic and microscopic features, differential diagnosis, diagnostic workup, and prognosis of all these different entities are discussed, with special emphasis on common differential diagnosis. PMID: 28797508 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 13, 2017 Category: Cancer & Oncology Authors: Cleven AHG, Hogendoorn PCW Tags: Surg Pathol Clin Source Type: research

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
Abstract At clinically relevant ixazomib concentrations, in vitro studies demonstrated that no specific cytochrome P450 (CYP) enzyme predominantly contributes to ixazomib metabolism. However, at higher than clinical concentrations, ixazomib was metabolized by multiple CYP isoforms, with the estimated relative contribution being highest for CYP3A at 42%. This multiarm phase 1 study (Clinicaltrials.gov identifier: NCT01454076) investigated the effect of the strong CYP3A inhibitors ketoconazole and clarithromycin and the strong CYP3A inducer rifampin on the pharmacokinetics of ixazomib. Eighty-eight patients were enr...
Source: Clinical Lymphoma and Myeloma - August 11, 2017 Category: Cancer & Oncology Authors: Gupta N, Hanley MJ, Venkatakrishnan K, Bessudo A, Rasco DW, Sharma S, O'Neil BH, Wang B, Liu G, Ke A, Patel C, Rowland Yeo K, Xia C, Zhang X, Esseltine DL, Nemunaitis J Tags: J Clin Pharmacol Source Type: research

A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
Abstract The oral proteasome inhibitor ixazomib is approved in multiple countries in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least 1 prior therapy. Two oral capsule formulations of ixazomib have been used during clinical development. This randomized, 2-period, 2-sequence crossover study (Clinicaltrials.gov identifier NCT01454076) assessed the relative bioavailability of capsule B in reference to capsule A in adult patients with advanced solid tumors or lymphoma. The study was conducted in 2 parts. In cycle 1 (pharmacokinetic cycle), p...
Source: Clinical Lymphoma and Myeloma - August 7, 2017 Category: Cancer & Oncology Authors: Hanley MJ, Gupta N, Venkatakrishnan K, Bessudo A, Sharma S, O'Neil BH, Wang B, van de Velde H, Nemunaitis J Tags: J Clin Pharmacol Source Type: research

Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population.
Abstract Hairy cell leukemia (HCL) is a rare hematologic malignancy with high response rates and long progression-free survival (PFS) after treatment with purine nucleoside analogs (PNAs; Pentostatin/Cladribine). However, treatment is not curative, and subsequent treatment at relapse is often required. Rechallenge with a purine analog is commonly implemented despite limited data regarding the efficacy of this approach. We retrospectively analyzed 61 consecutive patients with HCL diagnosed between 1995 and 2013 at Cleveland Clinic. Median follow-up was 72 months (3-193). Cladribine as first-line therapy was adminis...
Source: Clinical Lymphoma and Myeloma - July 14, 2017 Category: Cancer & Oncology Authors: Madanat YF, Rybicki L, Radivoyevitch T, Jagadeesh D, Dean R, Pohlman B, Kalaycio M, Sekeres MA, Smith MR, Hill BT Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Characteristics of Vitamin B12 Deficiency in Patients With Plasma Cell Disorders.
Abstract BACKGROUND: Although increased rates of vitamin B12 deficiency have been reported in patients with plasma cell dyscrasias (PCDs), no mechanism has been identified. Excess free light chains (FLCs) could disrupt the renal proximal tubule receptors where B12 is reabsorbed. We sought to characterize the relationship between B12 deficiency and PCDs. We hypothesized that rates of B12 deficiency would be highest in patients with PCDs with high FLC burdens. METHODS: We reviewed the electronic medical records of 501 patients who met inclusion criteria (diagnosed PCD with documented serum B12 and FLC leve...
Source: Clinical Lymphoma and Myeloma - July 12, 2017 Category: Cancer & Oncology Authors: Braschi C, Doucette J, Chari A Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Cancer incidence in the AGRICAN cohort study (2005-2011).
CONCLUSION: We found a decreased incidence for tobacco-related cancers and an increased incidence of prostate cancers, skin melanoma and multiple myeloma. Specific subgroups had a higher cancer incidence related to occupational status and pesticide use. PMID: 28709062 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 11, 2017 Category: Cancer & Oncology Authors: Lemarchand C, Tual S, Levêque-Morlais N, Perrier S, Belot A, Velten M, Guizard AV, Marcotullio E, Monnereau A, Clin B, Baldi I, Lebailly P, AGRICAN group Tags: Cancer Epidemiol Source Type: research

The oncologic burden of hepatitis C virus infection: A clinical perspective.
Abstract Answer questions and earn CME/CNE Chronic hepatitis C virus (HCV) infection affects millions of people worldwide and is associated with cancer. Direct-acting antivirals (DAAs) have changed HCV treatment paradigms, but little is known about the management of HCV infection in patients with cancer. The substantial burden of HCV infection and the inconclusive evidence regarding its detection and management in patients with cancer prompted the authors to review the literature and formulate recommendations. Patients for whom HCV screening is recommended included all patients with hematologic malignancies, hemat...
Source: Clinical Lymphoma and Myeloma - July 6, 2017 Category: Cancer & Oncology Authors: Torres HA, Shigle TL, Hammoudi N, Link JT, Samaniego F, Kaseb A, Mallet V Tags: CA Cancer J Clin Source Type: research

Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and S ézary Syndrome.
Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome. Clin Lymphoma Myeloma Leuk. 2017 Jun 24;: Authors: Kann BH, Park HS, Yeboa DN, Aneja S, Girardi M, Foss FM, Roberts KB, Wilson LD Abstract BACKGROUND: Management of mycosis fungoides and Sézary syndrome (MF/SS) is complex, and randomized evidence to guide treatment is lacking. The institutional treatment volumes for MF/SS might vary widely nationally and influence patient survival. PATIENTS AND METHODS: Using the National Cancer Database, we identified patients with a diagnosis of MF/SS ...
Source: Clinical Lymphoma and Myeloma - June 24, 2017 Category: Cancer & Oncology Authors: Kann BH, Park HS, Yeboa DN, Aneja S, Girardi M, Foss FM, Roberts KB, Wilson LD Tags: Clin Lymphoma Myeloma Leuk Source Type: research

UK consensus statement on the use of plerixafor to facilitate autologous Peripheral Blood Stem Cell collection to support high-dose chemoradiotherapy for patients with malignancy.
Abstract Plerixafor is a CXC chemokine receptor (CXCR4) antagonist that mobilizes stem cells in the peripheral blood. It is indicated (in combination with granulocyte-colony stimulating factor [G-CSF]) to enhance the harvest of adequate quantities of cluster differentiation (CD) 34+ cells for autologous transplantation in patients with lymphoma or multiple myeloma whose cells mobilize poorly. Strategies for use include delayed re-mobilization after a failed mobilization attempt with G-CSF, and rescue or pre-emptive mobilization in patients in whom mobilization with G-CSF is likely to fail. Pre-emptive use has the ...
Source: Clinical Lymphoma and Myeloma - June 20, 2017 Category: Cancer & Oncology Authors: Douglas KW, Gilleece M, Hayden P, Hunter H, Johnson PRE, Kallmeyer C, Malladi RK, Paneesha S, Pawson R, Quinn M, Raj K, Richardson D, Robinson S, Russell N, Snowden J, Sureda A, Tholouli E, Thomson K, Watts M, Wilson KM Tags: J Clin Apher Source Type: research